Narimon Honarpour

12.3k total citations · 4 hit papers
51 papers, 3.8k citations indexed

About

Narimon Honarpour is a scholar working on Surgery, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Narimon Honarpour has authored 51 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Surgery, 13 papers in Economics and Econometrics and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Narimon Honarpour's work include Lipoproteins and Cardiovascular Health (32 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (9 papers). Narimon Honarpour is often cited by papers focused on Lipoproteins and Cardiovascular Health (32 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers) and Pharmaceutical Economics and Policy (9 papers). Narimon Honarpour collaborates with scholars based in United States, United Kingdom and Australia. Narimon Honarpour's co-authors include Scott M. Wasserman, Frederick J. Raal, Robert C. Scott, Evan A. Stein, Marc S. Sabatine, Robert P. Giugliano, Feng Xu, Anthony Keech, Terje R. Pedersen and Xiaodong Wang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Narimon Honarpour

50 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

2014 553 citations Frederick J. Raal, Narimon Honarpour et al. The Lancet profile →
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. The Lancet Diabetes & Endocrinology profile →
Cognitive Function in a Randomized Trial of Evolocumab

2017 329 citations Robert P. Giugliano, François Mach et al. New England Journal of Medicine profile →
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

2024 115 citations Murielle M. Véniant, Shu-Chen Lu et al. Nature Metabolism profile →

Peers

Countries citing papers authored by Narimon Honarpour

Since Specialization

Citations

This map shows the geographic impact of Narimon Honarpour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narimon Honarpour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narimon Honarpour more than expected).

Fields of papers citing papers by Narimon Honarpour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narimon Honarpour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narimon Honarpour. The network helps show where Narimon Honarpour may publish in the future.

Co-authorship network of co-authors of Narimon Honarpour

This figure shows the co-authorship network connecting the top 25 collaborators of Narimon Honarpour. A scholar is included among the top collaborators of Narimon Honarpour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narimon Honarpour. Narimon Honarpour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings breakdown → 2024 ·Nature Metabolism ·Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan, Renée Komorowski, Shanaka Stanislaus, Yuan Cheng, Bin Wu, James R. Falsey, Todd Hager, Veena A. Thomas, (unknown), Lucie Sharpsten, (unknown), (unknown), (unknown), Rajneet K. Oberoi, Jane R. Parnes, Narimon Honarpour, Joel Neutel, Jennifer L. Strande	115
2	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis 2020 ·Stroke ·Robert P. Giugliano, Terje R. Pedersen, Jeffrey L. Saver, Peter S. Sever, Anthony Keech, Erin A. Bohula, Sabina A. Murphy, Scott M. Wasserman, Narimon Honarpour, Huei Wang, Armando Lira Pineda, Marc S. Sabatine, (unknown)	114
3	Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER 2019 ·Circulation ·Bariş Gencer, François Mach, Sabina A. Murphy, Gaetano Maria De Ferrari, Kurt Huber, Basil S. Lewis, Jorge Ferreira, Christopher E. Kurtz, Huei Wang, Narimon Honarpour, Anthony Keech, Peter S. Sever, Terje R. Pedersen, Marc S. Sabatine, Robert P. Giugliano	1
4	RS13. Risk of Major Adverse Limb Events and Benefits of Evolocumab in Patients With Peripheral Artery Disease by History of Prior Peripheral Revascularization 2019 ·Journal of Vascular Surgery ·Patrice Nault, Marc P. Bonaca, Robert P. Giugliano, Narimon Honarpour, Anthony Keech, Peter Sever, Terje R. Pedersen, Marc S. Sabatine	1
5	EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF 2019 ·Journal of the American College of Cardiology ·John R. Teerlink, G. Michael Felker, John J.V. McMurray, Scott D. Solomon, John G.F. Cleland, Steven R. Goldsmith, Christopher E. Kurtz, Gustavo Büchele, Jason C. Legg, Fady I. Malik, Narimon Honarpour	1
6	Association Between Systolic Ejection Time and Outcomes in Heart Failure by Ejection Fraction 2019 ·European Journal of Heart Failure ·Priyesh Patel, Andrew P. Ambrosy, Matthew Phelan, Fawaz Alenezi, Karen Chiswell, Melissa K. Van Dyke, (unknown), Narimon Honarpour, Eric J. Velazquez	20
7	Inflammatory and Cholesterol Risk in the FOURIER Trial 2018 ·Circulation ·Erin A. Bohula, Robert P. Giugliano, Lawrence A. Leiter, Subodh Verma, Jeong‐Gun Park, Peter Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A. Murphy, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine	193
8	Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial 2017 ·Circulation ·Sabina A. Murphy, Terje R. Pedersen, Zbigniew Gaciong, R Češka, М. В. Ежов, Derek Connolly, (unknown), J. Wouter Jukema, (unknown), Matti J. Tikkanen, Canqing Yu, Stephen D. Wiviott, Christopher E. Kurtz, Narimon Honarpour, Robert P. Giugliano, Anthony Keech, Peter Sever, Marc S. Sabatine	3
9	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study 2017 ·The Lancet Diabetes & Endocrinology ·Frederick J. Raal, G. Kees Hovingh, Dirk Blom, Raúl D. Santos, Mariko Harada‐Shiba, Éric Bruckert, Patrick Couture, Handrean Soran, Gerald F. Watts, Christopher E. Kurtz, Narimon Honarpour, Lihua Tang, (unknown), Scott M. Wasserman, Evan A. Stein	161
10	Cognitive Function in a Randomized Trial of Evolocumab breakdown → 2017 ·New England Journal of Medicine ·Robert P. Giugliano, François Mach, Kenton H. Zavitz, Christopher E. Kurtz, (unknown), Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine, Peter S. Sever, Jennifer G. Robinson, Narimon Honarpour, Scott M. Wasserman, Brian R. Ott	329
11	Abstract 13226: Shorter Left Ventricular Ejection Time is Associated With Adverse Outcomes in Heart Failure Patients With Reduced Ejection Fraction 2016 ·Circulation ·Priyesh Patel, Matthew Phelan, (unknown), Karen Chiswell, Melissa K. Van Dyke, (unknown), Fawaz Alenezi, Narimon Honarpour, Eric J. Velazquez	1
12	REDUCTION IN LIPOPROTEIN (A) WITH EVOLOCUMAB: ELUCIDATION OF THE ROLE OF THE LDL RECEPTOR FROM CLINICAL TRIALS AND IN-VITRO MODELS 2016 ·Journal of the American College of Cardiology ·Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Dirk Blom, Nabil G. Seidah, Narimon Honarpour, Armando Lira Pineda, Allen Xue, Simon Jackson, (unknown), Matthew Peach, Ransi Somaratne, Scott M. Wasserman, Robert C. Scott, Evan A. Stein	1
13	CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES 2015 ·Journal of the American College of Cardiology ·Evan A. Stein, Michael J. Koren, Narimon Honarpour, Christopher E. Kurtz, Jingyuan Yang, Scott M. Wasserman, Frederick J. Raal	5
14	LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES 2015 ·Journal of the American College of Cardiology ·Michael J. Koren, Robert S. Rosenson, Bobby V. Khan, Narimon Honarpour, Mary Elliott, Ransi Somaratne, Scott M. Wasserman, Erik S.G. Stroes	6
15	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial 2015 ·American Heart Journal ·Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Huei Wang, (unknown), Scott M. Wasserman, Robert C. Scott, Peter Sever, Terje R. Pedersen	130
16	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial breakdown → 2014 ·The Lancet ·Frederick J. Raal, Narimon Honarpour, Dirk Blom, G. Kees Hovingh, Feng Xu, Robert C. Scott, Scott M. Wasserman, Evan A. Stein	553
17	F-box Protein FBXL16 Binds PP2A-B55α and Regulates Differentiation of Embryonic Stem Cells along the FLK1+ Lineage 2014 ·Molecular & Cellular Proteomics ·Narimon Honarpour, Christopher M. Rose, Justin Brumbaugh, (unknown), R. L. Graham, Michael J. Sweredoski, Sonja Hess, Joshua J. Coon, Raymond J. Deshaies	23
18	Loss of Apaf-1 leads to partial rescue of the HAND2-null phenotype 2004 ·Developmental Biology ·(unknown), Narimon Honarpour, Joachim Herz, Deepak Srivastava	14
19	Embryonic neuronal death due to neurotrophin and neurotransmitter deprivation occurs independent of Apaf-1 2001 ·Neuroscience ·Narimon Honarpour, Katsuhiko Tabuchi, James M. Stark, (unknown), Thomas C. Südhof, Luis F. Parada, (unknown), James A. Richardson, Joachim Herz	18
20	Adult Apaf-1-Deficient Mice Exhibit Male Infertility 2000 ·Developmental Biology ·Narimon Honarpour, Chunying Du, James A. Richardson, Robert E. Hammer, Xiaodong Wang, Joachim Herz	172

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact